FYI
Below is one of the slides from the slide deck presented at AGM 2022
We can cross out the non disclosed active/payload for Starpharma’s DEP® HER-2 ADC as it has now been released
HER2-targeted DEP® SN-38 ADC comprises a HER2-directed antibody, trastuzumab, linked to DEP® dendrimers loaded with the topoisomerase I inhibitor, SN-38, which is the active metabolite of irinotecan
Starpharma’s HER2-targeted DEP® SN-38 ADC comprises a HER2-directed antibody, trastuzumab, linked to DEP® dendrimers loaded with the topoisomerase I inhibitor, SN-38, which is the active metabolite of irinotecan
FYI Below is one of the slides from the slide deck presented at...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
13.0¢ |
Change
0.005(4.00%) |
Mkt cap ! $54.36M | |||
| Open | High | Low | Value | Volume |
| 13.0¢ | 13.0¢ | 12.0¢ | $53.97K | 420.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 70507 | 12.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 13.0¢ | 493895 | 3 |
View Market Depth
| Last trade - 15.14pm 19/09/2025 (20 minute delay) ? |
| SPL (ASX) Chart |